Drug Trial Radar · NCT01443858
Meclizine as a Potential Smoking Cessation Treatment
Last checked: Nov 20, 2026Latest source record: Aug 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Aug 2011
Primary completion
Dec 2012
Study completion Jul 2013
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Philip Morris USA, Inc.
- First posted
- Sep 30, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether meclizine, an antihistamine used to prevent or treat motion sickness, can help smokers quit smoking. This study will also investigate the potential relationship between genes you have inherited and success in quitting smoking.
Conditions
- Smoking Cessation
Interventions
MeclizineDrug
Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
Nicotine PatchDrug
Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily. Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.
PlaceboDrug
Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 1Time frame: After 1 week of treatment (relative to baseline)
- Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 3Time frame: After 3 weeks of treatment (relative to baseline)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Duke Center for Nicotine and Smoking Cessation Research
Charlotte, North Carolina
Duke Center for Nicotine and Smoking Cessation Research
Durham, North Carolina
Duke Center for Nicotine and Smoking Cessation Research
Raleigh, North Carolina
Duke Center for Nicotine and Smoking Cessation Research
Winston-Salem, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.